PRDX5

Across TCGA pan-cancer cohorts, PRDX5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRDX5 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PRDX5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PRDX5 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where PRDX5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.595	0.328	.001	46	view →
LUAD	OS	Median	II,III,IV	1.000	0.862	.004	41	view →
CCRCC	OS	Median	II,III,IV	0.575	0.865	.003	20	view →
COAD	DFS	Tertile	All	1.000	0.909	.025	18	view →
LSCC	OS	Median	All	0.697	0.894	.016	5	view →
HNSC	DFS	Median	III,IV	0.881	0.681	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRDX5–PDAC (OS)

Open the PDAC breakdown →